Healthcare resource use following addition of montelukast to budesonide compared to doubling the dose of budesonide in patients with inadequately controlled asthma (COMPACT trial)

D. B. Price, Q. Zhang, V. Sazonov Kocevar, P. G. Polos, D. D. Yin (Aberdeen, United Kingdom; Whitehouse Station, United States Of America)

Source: Annual Congress 2004 - Current treatments for allergic rhinitis and asthma
Session: Current treatments for allergic rhinitis and asthma
Session type: Thematic Poster Session
Number: 855
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. B. Price, Q. Zhang, V. Sazonov Kocevar, P. G. Polos, D. D. Yin (Aberdeen, United Kingdom; Whitehouse Station, United States Of America). Healthcare resource use following addition of montelukast to budesonide compared to doubling the dose of budesonide in patients with inadequately controlled asthma (COMPACT trial). Eur Respir J 2004; 24: Suppl. 48, 855

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Health care resource utilization following addition of montelukast or salmeterol to fluticasone in patients with inadequately controlled asthma (IMPACT trial)
Source: Eur Respir J 2004; 24: Suppl. 48, 127s
Year: 2004

Adding montelukast versus doubling the budesonide dose in persistent asthma: a subgroup analysis of the COMPACT study
Source: Eur Respir J 2002; 20: Suppl. 38, 388s
Year: 2002

A multi-centre doubleblind randomised study examining the clinical outcome of treatment of the first asthma exacerbation with salmeterol xinafoate/fluticasone propionate combination product versus prednisolone
Source: Eur Respir J 2003; 22: Suppl. 45, 287s
Year: 2003

Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: a worldwide, randomised, effectiveness trial (RELIEF Study)
Source: Eur Respir J 2002; 20: Suppl. 38, 44s
Year: 2002

Healthcare costs are reduced when asthma is treated with budesonide and formoterol in a single inhaler compared with the same medication via separate inhalers
Source: Eur Respir J 2001; 18: Suppl. 33, 54s
Year: 2001

Fluticasone/formoterol combined in a single aerosol inhaler vs budesonide/formoterol for the treatment of asthma: A non-inferiority trial
Source: Annual Congress 2011 - Asthma: control and treatment
Year: 2011

Eight weeks of treatment with tiotropium plus fluticasone (t+f) produces an equally effective therapeutic response as salmeterol plus fluticasone (s+f) in subjects with moderate-to-severe asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009


Low dose salmeterol/fluticasone propionate combination (SFC) via metered dose inhaler (MDI) improves asthma control and quality of life in patients not well controlled on inhaled steroids (ICS)
Source: Eur Respir J 2002; 20: Suppl. 38, 47s
Year: 2002

Budesonide and formoterol in mild persistent asthma compared with doubling the dose of budesonide - a cost-effectiveness analysis
Source: Eur Respir J 2001; 18: Suppl. 33, 517s
Year: 2001

Total costs according to reliever use of formoterol turbuhaler in asthma: results from the RELIEF worldwide randomized effectiveness study, stratified by maintenance medication levels
Source: Eur Respir J 2002; 20: Suppl. 38, 43s
Year: 2002

Cost-effectiveness of formoterol turbuhaler versus salbutamol as reliever therapy in asthma: results from the RELIEF worldwide randomised effectiveness study
Source: Eur Respir J 2002; 20: Suppl. 38, 43s
Year: 2002

Is overall asthma control being achieved? A hypothesis-generating study
Source: Eur Respir J 2001; 17: 589-595
Year: 2001



A single-dose double-blind study comparing efficacy of two dry powder inhalers containing budesonide and formoterol in asthmatic patients
Source: International Congress 2016 – Asthma management
Year: 2016


Effect of combination fluticasone propionate and salmeterol diskhaler in treatment of moderate to severe asthma: comparison of initial high dose, constant medium dose and placebo
Source: Eur Respir J 2001; 18: Suppl. 33, 123s
Year: 2001

24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma, and comparison with formoterol
Source: Annual Congress 2008 - New treatments for asthma
Year: 2008

Effect of salmeterol/fluticasone propionate versus tiotropium bromide on exacerbations: the INSPIRE study (investigating new standards for prophylaxis in reduction of exacerbations)
Source: Annual Congress 2007 - Primary care respiratory problems
Year: 2007


Efficacy and safety of combined mometasone furoate/formoterol 100/10μg twice daily in subjects with asthma inadequately controlled on low-dose inhaled corticosteroids
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010


Randomized clinical trial (RCT) comparing formoterol vs. salbutamol plus ipratropium bromide in the treatment of acute asthma exacerbation (AE) at emergency room (ER)
Source: Eur Respir J 2005; 26: Suppl. 49, 503s
Year: 2005

Addition of formoterol Turbuhaler® to budesonide Turbuhaler® is safe and well tolerated in the long-term treatment of mild asthma: results from the OPTIMA trial
Source: Eur Respir J 2001; 18: Suppl. 33, 330s
Year: 2001

Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 509s
Year: 2004